IGLON5 and Apnea: Anti-IgLON5 antibodies (IgLON5-IgG) from serum and cerebrospinal fluid (CSF) were first described clinically in a cohort of patients with sleep apnoea, non-rapid eye movement (non-REM) and REM parasomnias, and stridor in 2014 [1].